Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinfangfeng teabag is a traditional Chinese medicine (TCM) herbal tea developed by Jiangxi Shouzheng Pharmaceutical for the treatment of the common cold, specifically targeting the Qi-deficiency pattern (气虚感冒). It is currently in Phase II clinical development in China. The formulation is designed as a teabag for oral administration, intended to be taken over a 14-day course. As a TCM product, its therapeutic approach likely involves a combination of herbal ingredients such as Saposhnikovia divaricata (Fangfeng) and other botanicals aimed at tonifying vital energy (Qi) and expelling pathogenic factors. A randomized, double-blind, placebo-controlled multicenter trial (CTR20262096) is evaluating its efficacy and safety in patients with the specified cold pattern.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinfangfeng teabag.